We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > efgartigimod

News List

Argenx Announces Publication of Phase 3 ADAPT Trial Results of Efgartigimod for the Treatment of Generalized Myasthenia Gravis in The Lancet Neurology firstwordpharma
June 17, 2021
argenx (Euronext & Nasdaq: ARGX), today announced that The Lancet Neurology has published pivotal trial results from the Phase 3 ADAPT trial of efgartigimod, an FcRn antagonist, for the treatment of adults living with generalized myasthenia gravis (gMG).
Elektrofi, Argenx Enter Collaboration and License Agreement contractpharma
April 28, 2021
Elektrofi, a Boston-based biotechnology company focused on drug formulation and delivery innovations, has entered into a collaboration and license agreement with argenx to explore new subcutaneous formulations for therapeutic products directed at the ...